Up 178% Overnight, Should Investors Buy Valens (TSX:VLNS) Stock?

Valens (TSX:VLNS) stock soared 178% in early morning trading after news from its CEO and a Nasdaq listing in the works.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Valens (TSX:VLNS) shares soared 178% in early-morning trading on Nov. 18 after the company commenced a three-to-one stock split. This came after meeting requirements to list on the Nasdaq. Shares of Valens stock went from $1.78 to $5.28 overnight from the stock split. 

What happened?

The stock split is another step towards the listing on the Nasdaq for Valens stock. The cannabis provider has now met the requirements that could see the company listed on the Nasdaq before the end of the year.

“This announcement represents a milestone towards the listing of Valens’s common shares on Nasdaq,” said Tyler Robson, CEO of The Valens Company. “With the recent progress in our application, paired with the share consolidation to meet minimum listing requirements, Valens expects to commence trading on Nasdaq before the end of 2021.”

The jump comes also as Robson received a Canada’s “Top 40 Under 40” award. Beyond his “team player” attitude, Robson led four major acquisitions. This included that of LYF Technologies, Verse Cannabis, Citizen Stash, and Green Roads in Florida.

This last acquisition marks Valens stock entry into the United States. And with more rumours coming out that federal legalization could happen sooner as opposed to later, Valens stock could be a strong entry point — especially as other cannabis stocks crash around it.

So what?

With only one acquisition in the last year aimed at the U.S., should investors really get excited about federal legalization and Valens stock? In short: yes. The cannabis stock also announced its on the way to having a Nasdaq listing. This could boost the share price even higher with access to the U.S. and could mean further U.S. acquisitions in the future.

Furthermore, we can’t ignore that other cannabis company CEOs simply did not make the cut on the “40 Under 40” list. In a time when cannabis companies are struggling to make ends meet, Valens stock seems to be the odd one out.

Of course, the nominees are chosen on more than the numbers, including sustainability and market leadership. However, investors can’t ignore Valens stock’s finances. The company saw gross revenue rise 32.7% year over year during its third quarter, with provincial sales up 20% compared to the second quarter.

It also closed its Citizen Stash acquisition. And according to Valens, the “strategic acquisition of Citizen Stash expected to propel Valens’s asset-light entry into the flower and pre-roll segments, the two largest categories in the Canadian cannabis market currently accounting for over 70% of retail sales.”

Now what?

Valens stock ended the quarter with about $31 million on the books. This while other cannabis stocks try and make a profit. The acquisitions of late may be just the tip of the iceberg, as the company continues to bring in more cash.

Analysts have been touting Valens stock as undervalued for a while, marking it worth around $4 per share, while it traded around $1. During the latest earnings report, analysts bumped it even higher thanks to acquisitions and entry into the U.S.

Sales should continue to accelerate thanks to the acquisitions into full year 2022, according to analysts. Further, there is an entry into Quebec, a manufacturing agreement, and full-quarter acquisition sales to look forward to.

So, yes, even with Valens stock entering a stock split, according to analysts, it’s still a buy. The company has remained responsible and focused on shareholder interests in growing sales at a steady pace.

Shares currently trade at $5 as of writing, up 137% year to date. Furthermore, analysts give it a potential upside of 131% for the next year! That could be even higher taking the recent split into consideration.

Should you invest $1,000 in BCE right now?

Before you buy stock in BCE, consider this:

The Motley Fool Stock Advisor Canada analyst team just identified what they believe are the Top Stocks for 2025 and Beyond for investors to buy now… and BCE wasn’t one of them. The Top Stocks that made the cut could potentially produce monster returns in the coming years.

Consider MercadoLibre, which we first recommended on January 8, 2014 ... if you invested $1,000 in the “eBay of Latin America” at the time of our recommendation, you’d have $21,345.77!*

Stock Advisor Canada provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month – one from Canada and one from the U.S. The Stock Advisor Canada service has outperformed the return of S&P/TSX Composite Index by 24 percentage points since 2013*.

See the Top Stocks * Returns as of 4/21/25

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Amy Legate-Wolfe has no position in any of the stocks mentioned. The Motley Fool recommends The Valens Company Inc.

Confidently Navigate Market Volatility: Claim Your Free Report!

Feeling uneasy about the ups and downs of the stock market lately? You’re not alone. At The Motley Fool Canada, we get it — and we’re here to help. We’ve crafted an essential guide designed to help you through these uncertain times: "5-Step Checklist: How to Prepare Your Portfolio for Volatility."

Don't miss out on this opportunity for peace of mind. Just click below to learn how to receive your complimentary report today!

Get Our Free Report Today

More on Cannabis Stocks

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Stocks for Beginners

Buy the Dip Before It’s Too Late: This Canadian Stock Won’t Stay Cheap Forever

Investors might think that cannabis stocks are out, but this one could be the top Canadian stock to consider.

Read more »

a person watches a downward arrow crash through the floor
Stocks for Beginners

Plummet Alert: Is This TSX Growth Stock a Bargain or a Falling Knife?

This growth stock was once a major winner, but can investors wait for more?

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

What to Know About Canadian Cannabis Stocks for 2025

Let's dive into two top Canadian cannabis stocks and where they may be headed from here (given the recent moves…

Read more »

Researcher works in hemp field
Cannabis Stocks

Aurora Cannabis Stock Is up 46% in 2025: Are Investors Going From 5 Years of Pain to a 2025 Gain?

Shares of Aurora Cannabis have staged a comeback in 2025, outpacing the broader markets comfortably. Is ACB stock a good…

Read more »

A plant grows from coins.
Stocks for Beginners

3 Growth Stocks That Could Skyrocket in 2025 and Beyond

It could be a big year for these sectors, and these growth stocks in particular throughout 2025.

Read more »

money goes up and down in balance
Tech Stocks

2 TSX Stocks to Buy and 2 to Avoid in the Looming Trade War

The looming U.S.-Canada trade war has changed the business environment. Here are some TSX stocks to buy and avoid in…

Read more »

space ship model takes off
Cannabis Stocks

2 Canadian Stocks With Strong Momentum for 2025

Celestica Inc. (TSX:CLS) stock and Dollarama (TSX:DOL) stock have sustained strong price growth momentum for a long time.  Here’s why…

Read more »

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Pot Stocks: Buy, Sell, or Hold in 2025?

Cannabis stocks remain a bit risky, but could long-term investors be in for more pain or far more profits?

Read more »